We herein present a rare case of myocardial metastases from intrahepatic cholangiocarcinoma. The patient was a 68-year-old man diagnosed with stage IVb intrahepatic cholangiocarcinoma. Growing low-density nodules at the cardiac interventricular septum and the left lateral wall were found on contrast enhanced computed tomography (CECT). He died and an autopsy was performed. Intrahepatic cholangiocarcinoma was found to have metastasized to the myocardium, and these myocardial metastases conformed to the low-density nodules detected on CECT. A hilar nodule in the lung was revealed to be lung squamous cell carcinoma. This was a rare case of intrahepatic cholangiocarcinoma with myocardial metastases and lung squamous cell carcinoma.
Introduction
Cardiac metastases have been found in up to 25% of postmortem patients who died from malignancies, and recent developments in diagnostic methods, such as new imaging modalities, has led to an increased frequency of detection (1, 2) . On the other hand, cardiac metastases are rarely detected before death, as they usually remain clinically silent. However, sudden death has been reported in some cases of myocardial metastases, which are a rare form of heart metastasis (1). These can provoke atrial and ventricular heart rhythm disturbances and conduction defects, including complete atrioventricular block. Myocardial infarction can also be caused by the invasion or compression of a coronary artery. An antemortem diagnosis of myocardial metastases is clinically essential for preventing such problems and avoiding sudden death. We herein present a rare case of double primary cancer in which the antemortem diagnosis of myocardial metastases was possible.
Case Report
A 68-year-old man was referred to our hospital with symptoms of epigastric discomfort and body weight loss. The patient had undergone an appendectomy when he was 20 years old and had a history of prostatic hypertrophy. He had smoked 30 cigarettes per day for 45 years. Abdominal dynamic computed tomography (CT) scans revealed that multiple irregular tumors of low attenuation with slight rim enhancement were present in the right lobe of the liver. There was localized dilation of the intrahepatic bile ducts around the tumors and regional lymphadenopathy ( Fig. 1a and b) . A laboratory examination showed elevation of CA19-9 (5,790 U/mL; normal range, <37.7 U/mL) and CA125 (405.4 U/mL; normal range, <25 U/mL). An upper gastrointestinal endoscopy and colonoscopy showed no significant abnormalities. After obtaining written informed consent, a percutaneous liver biopsy was performed to obtain a histopathological diagnosis. Moderately differentiated adeno- carcinoma with abundant fibrous stroma supported a diagnosis of the mass-forming type of intrahepatic cholangiocarcinoma. A chest CT scan revealed a solitary left hilar nodule (Fig. 2) . Although a histological examination of this nodule was not performed, we considered it to be a lung metastasis of intrahepatic cholangiocarcinoma considering the size of the primary tumor and the results of other examinations.
The patient's clinical staging was considered to be T3N1 M1 (stage IVb) according to the Union Internationale Contre le Cancer/American Joint Committee on Cancer Tumor Node Metastasis (AJCC/UICC TNM) staging system. We started systemic chemotherapy using gemcitabine with weekly intravenous administration at a dose of 1,000 mg/m 2 for three weeks, every four weeks, and repeated these cycles for up to 16 weeks on an outpatient basis. However, the patient developed progressive disease. A follow-up contrastenhanced CT scan performed at 1 month after the diagnosis revealed low-density nodules in the cardiac interventricular septum and left lateral wall (Fig. 3a) , and CT scans at 5 months after the diagnosis showed these nodules to have grown (Fig. 3b) .
Subsequently, the patient developed somnolence and vomiting. Laboratory examinations showed hypercalcemia (16.5 mg/dL; normal range, 8.5 to 10.2 mg/dL). The patient was immediately hospitalized. His temperature and pulse rate were 36.9 and 72 beats per min, respectively. There was a 98% saturation of the patient's peripheral blood oxygen (room air) and his blood pressure was 124/78 mmHg. A physical examination showed mild dysarthria, poor finger-tonose test results and mild percussion tenderness in the right upper quadrant. The remainder of the examination revealed no significant abnormalities. The laboratory test results are shown in Table. The corrected calcium level was 17.5 mg/ dL. The levels of thyroid hormone, intact parathyroid hormone (PTH), angiotensin-converting enzyme, bone-type alkaline phosphatase and 1a,25(OH)2D3 were all within the normal limits. However, an elevation of the levels of cytokeratin 19 fragment (46 ng/mL; normal range, <2.0 ng/ mL), PTH-related protein-intact (PTHrP-intact), (16.9 pmol/ L; normal range, <1.1 pmol/L) and urine calcium (0.67 g/ day; normal range, 0.1 to 0.3 g/day) was seen. Magnetic resonance imaging (MRI) of the brain revealed no significant findings. A chest CT scan showed that the left hilar nodule had grown in size and mediastinal lymph node swelling was evident (Fig. 4) . Abdominal dynamic CT scans revealed bone metastases to the lumbar vertebra, lower thoracic vertebra and left ilium. The multiple low-attenuation irregular tumors in the liver and abdominal lymph nodes found at the initial diagnosis had become enlarged (Fig. 5 ). Portal vein occlusion and right lobar atrophy appeared. Since hypercalcemia with the elevation of PTHrP suggested humoral hypercalcemia of malignancy (HHM), which was considered to have caused the patients' symptoms, therapeutic procedures involving the infusion of normal saline, fu- rosemide, zoledronate, calcitonin and betamethasone were immediately started. On the 6th day of admission, the patient became alert. The corrected calcium level decreased to 8.9 mg/dL (serum calcium level, 7.2 mg/dL; and serum albumin level, 2.3 g/dL).
We then commenced radiation therapy for the bone metastases. The nodules in the cardiac interventricular septum and left lateral wall were further investigated. An electrocardiogram (ECG) revealed a non-specific T-wave depression, although an ECG at the patient's first visit showed no significant abnormalities ( Fig. 6a and b) . Echocardiography revealed a normal left ventricular function with an ejection fraction of 81% and a hypoechoic nodule in the interventricular septum and a small pericardial effusion (Fig. 7) . The nodule in the left lateral wall detected on dynamic CT could not be detected by echocardiography. We also planned a bronchoscopic examination to facilitate a biopsy and histopathological diagnosis of the left hilar nodule of the lung and mediastinal lymph nodes. However, we could not perform a biopsy because the patient developed a fever and jaundice. Laboratory tests showed the total bilirubin level to be 3.1 mg/dL; while the direct bilirubin level was 1.9 mg/ dL; the aspartate aminotransferase level was 114 IU/L; and the alanine aminotransferase level was 100 IU/L. This indicated the development of obstructive jaundice due to tumor progression. Although intravenous administration of antibiotics and endoscopic naso-biliary drainage were performed, the jaundice did not improve, thus suggesting that the tumors had caused the complete occlusion of the portal vein and hepatic failure.
On the 30th day of admission, the patient died, and an autopsy was performed after obtaining written informed consent from his family. A well-circumscribed nodule (20× 15 mm in size) was found in the cardiac interventricular septum and another nodule (15×15 mm in size) was found in the left lateral wall of the heart (Fig. 8a) . In the liver, a 13×11 mm nodule was found in the right lobe and multiple nodules of less than 10 mm in size were also found. A mi- croscopic examination revealed moderately differentiated adenocarcinoma with abundant fibrous stroma (Fig. 8b) . These findings were compatible with intrahepatic cholangiocarcinoma. The microscopic examination of the cardiac masses revealed adenocarcinoma in the myocardium (Fig. 8c) , thus suggesting metastases from the intrahepatic cholangiocarcinoma. Metastases to bone marrow, the abdominal and mediastinal lymph nodes, and the lungs were seen. In the left lung, a 5×15 mm nodule was found, and a microscopic examination revealed atypical nuclear cells with pearl formation (Fig. 8d) . These findings were compatible with poorly differentiated squamous cell carcinoma. Metastases to bone marrow, the pulmonary hilar lymph node and the liver were also observed.
Discussion
Tumors metastatic to the heart have rarely been observed, and few systematic studies have been devoted to this topic. Cardiac metastases have been reported to occur in from 2.3 to 25% of autopsy patients who died due to malignancies, and recent developments in diagnostic methods have led to an increase in the frequency of detection (1, 2) . In general, cardiac metastases are classified as pericardial, myocardial and endocardial according to their location in the heart (1, 2). Bussani et al. reported the frequency of occurrence of pericardial, myocardial and endocardial metastases to be 69.4%, 31.8% and 5%, respectively (2). Mukai et al. also reported almost identical frequencies of occurrence for these metastases, according to findings from 2,649 autopsies of patients with malignant tumors (2, 3) . The most common tumors with cardiac metastatic potential are malignant melanoma, lung cancer, leukemia, malignant lymphoma, breast cancer and esophageal cancer (1). Mukai et al. reported the corresponding rates of cardiac metastases from the abovementioned malignancies in postmortem patients to be 67.5%, 28.1%, 21.4%, 18.4%, 18.1% and 13.4%, respectively (3).
On the other hand, hepatobiliary malignancies rarely present as cardiac metastases. For example, the rate of cardiac metastasis in cholangiocarcinoma patients is reported to be 3.7%, while that in hepatocellular carcinoma patients is only 0.5% (3). Therefore, cardiac metastasis of intrahepatic cholangiocarcinoma, as seen in our case, is very rare; the patient presented with myocardial metastases, which is an unusual form of cardiac metastasis. To the best of our knowledge, ours is the first report of myocardial metastasis from intrahepatic cholangiocarcinoma, although in 2009 Chang et al. reported the first case of myocardial metastasis from extrahepatic cholangiocarcinoma (4) .
Cardiac metastases, including myocardial metastases, are usually asymptomatic. However, myocardial metastases can cause sudden death or other significant clinical problems such as syncope, and indeed, such cases have been previously reported. For example, myocardial metastases can provoke atrial and ventricular heart rhythm disturbances and conduction defects, including complete atrioventricular block (5) (6) (7) (8) (9) , and may cause myocardial infarction or angina pectoris as a result of invasion or compression of a coronary artery (1, (10) (11) (12) . Although there are no established therapeutic strategies, several reports have shown that, in patients whose myocardial metastasis caused complete atrioventricular block, pacemaker implantation or systemic chemotherapy might be effective (7, 8) . The frequency of myocardial metastasis will likely increase due to recent improvements being made in diagnostic methods. Therefore, antemortem detection of myocardial metastases is becoming increasingly common for clinicians, and the development of effective diagnostic and treatment strategies is essential to prevent cardiac issues and sudden death.
In the present case, there was no evidence from physical or laboratory examinations that were suggestive of the presence of myocardial metastasis. ECG findings that indicate myocardial metastasis are usually non-specific. However, ECG is valuable for observing metastases, since they can cause heart arrhythmias or ischemic changes depending on their location and size (1). Mukai et al. reported that in cases of cardiac metastases, 40.9% showed ST-T changes or T-wave abnormalities, 12.5% exhibited low voltage and 11.8% had conduction defects (3). In the present case, the ECG carried out at 5 months when the patients' myocardial metastases had worsened, showed non-specific T-wave abnormalities that had not been seen at the initial visit to our hospital. Echocardiography is therefore considered to be a useful method for the detection of cardiac metastases and their complications. It has also been reported to be useful for the detection of pericardial effusion with high sensitivity (1). Mukai et al. reported that in cases of cardiac metastases, echocardiography revealed pericardial effusion in 35%, cardiac dysfunction in 23%, and no significant findings in only 3% of cases and 17% (3) .
In a previous report, echocardiography demonstrated myocardial metastasis from cholangiocarcinoma as a hypoechoic mass with an irregular surface (4) . In the present case, echocardiography revealed a small amount of pericardial effusion and a low-density demarcated nodule in the interventricular septum. At autopsy, this nodule was proven to be myocardial metastasis from intrahepatic cholangiocarcinoma. The metastasis in the left lateral wall was not demonstrated using echocardiography, despite the fact that the operator had noticed its presence on CT scans. Since echocardiography is a method that is dependent on the skill of the operator, this may suggest that it is not always sensitive for the detection of myocardial metastases themselves. CT and MRI scans can determine the size and extension of tumor growth more precisely than echocardiography (1) . Although MRI scans were not performed in the present case, contrast-enhanced CT scans revealed low-density nodules in the cardiac interventricular septum and left lateral wall at 1 month after the diagnosis, and repeated CT scan findings revealed the time course of their growth. A heart autopsy demonstrated the exact sizes and anatomical locations of the tumors and confirmed that contrast-enhanced CT is a useful imaging modality for the detection of myocardial metastasis from intrahepatic cholangiocarcinoma.
Metastases can reach the heart by direct invasion or transvenous extension, or through the hematogenous or lymphatic routes. Myocardial metastasis arises preferentially by hematogenous spread. Tumor cells reach the epicardial and then the myocardial lymphatic system via the mediastinal lymph nodes (1, 2) . In the present case, tumor emboli of the portal vein were seen, although there was no invasion or tumor embolus of the hepatic vein or inferior vena cava. No pericardial metastases were observed, although metastases to the mediastinal lymph nodes were seen. These findings suggested that the myocardial metastases in our case were due to hematogenous spread.
Eighty percent of patients with hypercalcemia associated with malignancies are reported to show HHM. The condition is caused by the systemic secretion of PTHrP by malignant tumors. The most common tumor that causes hypercal- cemia is reported to be lung squamous cell carcinoma (13), although any tumor can cause this syndrome. The frequency of hypercalcemia associated with lung squamous cell carcinoma is reported to be 12.5 to 35% (14) . In our case, HHM and the elevation of the cytokeratin 19 fragments led us to consider the possibility of primary lung cancer, although unfortunately, we could not perform a bronchoscopic examination.
To the best of our knowledge, the present case report is the first describing double primary cancers of intrahepatic cholangiocarcinoma with myocardial metastasis and lung squamous cell carcinoma. A common risk factor associated with both cancers is smoking. Cigarettes are a well-known risk factor for lung squamous cell carcinoma. In addition, some studies have reported that smoking is also associated with intrahepatic cholangiocarcinoma (15, 16) . Our patient was a heavy smoker, and this could have been one of the causes of the double primary cancers that were observed.
In conclusion, clinicians should be alert to the possibility of myocardial metastasis in patients with intrahepatic cholangiocarcinoma, although such cases are rare. Contrastenhanced CT is a useful imaging modality for the detection of myocardial metastasis. In patients with a history of heavy smoking, the possibility of the presence of other cancers should therefore be considered.
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